With 900 advanced therapies currently under investigation and an expected 10 to 20 new therapy approvals each year from 2025 onwards, cell & gene therapy is going fast. But, it brings its own set of unique challenges to adapt.
How to orchestrate cell & gene therapy supply chains, different in all its aspects
About a year and a half ago, we were asked by a client in the US to help them implement capacity planning & detailed scheduling for manufacturing and quality operations in a CAR-T cell & gene therapy production plant. What are the insights that we......